INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
inMune Bio 2024年第一季度GAAP每股收益美元（0.61美元）未達到預期（0.54美元），銷售額爲14,000萬美元，未達到30.000萬美元的預期
INmune Bio (NASDAQ:INMB) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.54) by 12.96 percent. This is a 69.44 percent decrease over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $14.000 thousand which missed the analyst consensus estimate of $30.000 thousand by 53.33 percent. This is a 63.16 percent decrease over sales of $38.000 thousand the same period last year.
InMune Bio（納斯達克股票代碼：INMB）公佈的季度虧損爲每股0.61美元，比分析師普遍預期的0.54美元（0.54美元）低12.96％。這比去年同期每股虧損0.36美元（0.36美元）下降了69.44％。該公司公佈的季度銷售額爲14,000美元，比分析師普遍預期的3萬美元低53.33％。這比去年同期的38,000美元銷售額下降了63.16％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。